MYL's subsidiary obtains drug registration certificate for sodium hyaluronate eye drops
I'm PortAI, I can summarize articles.
MYL's wholly-owned subsidiary, Jiangxi MYL Meikang Pharmaceutical Co., Ltd., recently obtained the sodium hyaluronate eye drops drug registration certificate issued by the National Medical Products Administration. This approval will enrich the company's ophthalmic product line and enhance market competitiveness
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments